Forum Financial Management LP Acquires Shares of 35,140 Anavex Life Sciences Corp. (NASDAQ:AVXL)

Forum Financial Management LP bought a new position in Anavex Life Sciences Corp. (NASDAQ:AVXL) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor bought 35,140 shares of the biotechnology company’s stock, valued at approximately $200,000.

Several other institutional investors also recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in Anavex Life Sciences by 1.2% during the first quarter. Vanguard Group Inc. now owns 4,414,682 shares of the biotechnology company’s stock worth $22,471,000 after acquiring an additional 54,034 shares in the last quarter. Nwam LLC grew its stake in shares of Anavex Life Sciences by 4.8% in the 1st quarter. Nwam LLC now owns 836,730 shares of the biotechnology company’s stock worth $4,259,000 after buying an additional 38,437 shares during the last quarter. Jupiter Asset Management Ltd. increased its position in Anavex Life Sciences by 675.0% during the 1st quarter. Jupiter Asset Management Ltd. now owns 804,642 shares of the biotechnology company’s stock valued at $4,096,000 after buying an additional 700,812 shares in the last quarter. Renaissance Technologies LLC raised its stake in Anavex Life Sciences by 483.8% during the second quarter. Renaissance Technologies LLC now owns 466,437 shares of the biotechnology company’s stock valued at $1,968,000 after buying an additional 386,537 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in Anavex Life Sciences by 17.1% in the second quarter. Bank of New York Mellon Corp now owns 280,556 shares of the biotechnology company’s stock worth $1,184,000 after acquiring an additional 40,895 shares in the last quarter. 31.55% of the stock is currently owned by institutional investors.

Anavex Life Sciences Trading Up 5.5 %

Shares of AVXL opened at $7.70 on Wednesday. The company has a market cap of $652.93 million, a price-to-earnings ratio of -15.40 and a beta of 0.60. The business’s fifty day simple moving average is $5.60 and its two-hundred day simple moving average is $5.08. Anavex Life Sciences Corp. has a 12 month low of $3.25 and a 12 month high of $10.45.

Anavex Life Sciences (NASDAQ:AVXL) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01. During the same period in the previous year, the firm earned ($0.14) EPS. As a group, research analysts forecast that Anavex Life Sciences Corp. will post -0.55 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on AVXL shares. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Anavex Life Sciences in a research report on Monday. EF Hutton Acquisition Co. I raised shares of Anavex Life Sciences to a “strong-buy” rating in a report on Monday, July 22nd.

Anavex Life Sciences Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.